Saxenda Cost in 2026 — Liraglutide Real Prices vs Wegovy and Zepbound

Saxenda in 2026: the legacy AOM

Saxenda (liraglutide 3.0 mg) was the first modern GLP-1 approved for weight loss (2014). It’s been effectively outclassed by Wegovy (same manufacturer) on efficacy and by Zepbound on both efficacy and dosing convenience. It still has a place for pediatric patients and for specific clinical situations, but it’s no longer the default choice.

2026 price paths

• List price: ~$1,349/mo.
• Commercial insurance + savings card: $25/mo typical copay.
• Uninsured cash: $1,100–$1,300 at retail pharmacies.
• Medicare/Medicaid: Coverage varies; generally not covered for weight loss alone.

Saxenda vs Wegovy vs Zepbound (head-to-head)

• Efficacy: Saxenda ~8% TBWL; Wegovy ~15%; Zepbound ~22%.
• Dosing: Daily (Saxenda) vs weekly (Wegovy, Zepbound).
• Price (list): All three roughly $1,100–$1,350.
• Self-pay alternative: None for Saxenda; NovoCare vial ($499) for Wegovy; LillyDirect vial ($349–$499) for Zepbound.
• Pediatric: Saxenda yes (12+); Wegovy yes (12+); Zepbound no.

When Saxenda still makes clinical sense

1. Pediatric patients aged 12–17 where Wegovy isn’t tolerated or preferred.
2. Patients who plan pregnancy in the 3–6 month window (faster clearance than semaglutide).
3. Patients whose plan specifically covers Saxenda cheaper than Wegovy or Zepbound (rare, but real on older plan designs).
4. Patients with severe GI intolerance to higher-potency weekly GLP-1s who may tolerate lower-peak daily liraglutide.

Practical notes

• Saxenda titrates over 4 weeks: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg daily.
• Side-effect profile mirrors other GLP-1s (nausea, constipation, GI discomfort).
• Same boxed warning for medullary thyroid carcinoma / MEN2.
• Same pregnancy precaution as other GLP-1s — discontinue before TTC.